ProQR Therapeutics (NASDAQ:PRQR) Research Coverage Started at Oppenheimer

Oppenheimer started coverage on shares of ProQR Therapeutics (NASDAQ:PRQR) in a research note published on Thursday morning. The firm issued an outperform rating and a $9.00 price objective on the biopharmaceutical company’s stock.

Several other research analysts have also recently weighed in on the company. Zacks Research raised ProQR Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Thursday, November 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of ProQR Therapeutics in a research report on Thursday, January 22nd. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $6.80.

ProQR Therapeutics Price Performance

PRQR opened at $1.82 on Thursday. The business has a 50 day moving average price of $1.64 and a two-hundred day moving average price of $2.06. The company has a market capitalization of $191.49 million, a price-to-earnings ratio of -3.96 and a beta of 0.21. ProQR Therapeutics has a 1-year low of $1.07 and a 1-year high of $3.10.

ProQR Therapeutics (NASDAQ:PRQR) last issued its quarterly earnings results on Thursday, March 12th. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.01). ProQR Therapeutics had a negative net margin of 255.83% and a negative return on equity of 61.64%. The firm had revenue of $5.50 million for the quarter, compared to analyst estimates of $6.12 million. Equities analysts expect that ProQR Therapeutics will post -0.31 EPS for the current fiscal year.

Institutional Investors Weigh In On ProQR Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Osaic Holdings Inc. boosted its stake in shares of ProQR Therapeutics by 59.6% during the 2nd quarter. Osaic Holdings Inc. now owns 12,050 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 4,500 shares in the last quarter. Persistent Asset Partners Ltd raised its position in shares of ProQR Therapeutics by 24.5% during the fourth quarter. Persistent Asset Partners Ltd now owns 45,154 shares of the biopharmaceutical company’s stock worth $91,000 after purchasing an additional 8,874 shares during the period. Diadema Partners LP raised its position in shares of ProQR Therapeutics by 6.2% during the fourth quarter. Diadema Partners LP now owns 167,532 shares of the biopharmaceutical company’s stock worth $338,000 after purchasing an additional 9,838 shares during the period. Raymond James Financial Inc. lifted its holdings in shares of ProQR Therapeutics by 15.2% during the third quarter. Raymond James Financial Inc. now owns 110,270 shares of the biopharmaceutical company’s stock valued at $235,000 after purchasing an additional 14,549 shares during the last quarter. Finally, OneDigital Investment Advisors LLC lifted its holdings in shares of ProQR Therapeutics by 23.1% during the third quarter. OneDigital Investment Advisors LLC now owns 80,000 shares of the biopharmaceutical company’s stock valued at $170,000 after purchasing an additional 15,000 shares during the last quarter. Institutional investors and hedge funds own 32.65% of the company’s stock.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V. is a clinical-stage biotechnology company dedicated to developing RNA-based therapies for severe genetic diseases. Utilizing its proprietary Axiomer® RNA editing platform, ProQR aims to correct disease-causing mutations directly at the messenger RNA level. The company’s pipeline features several investigational candidates, including sepofarsen (formerly QR-110) for Leber congenital amaurosis type 10, QR-421a targeting Usher syndrome and certain forms of retinitis pigmentosa, and QR-313 for dystrophic epidermolysis bullosa.

Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR maintains a significant presence in Cambridge, Massachusetts, to support its clinical research and regulatory initiatives.